deltatrials
Not Yet Recruiting PHASE2 INTERVENTIONAL 4-arm NCT05554419

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial

Sponsor: National Cancer Institute (NCI)

Updated 16 times since 2022 Last updated: Mar 12, 2026 Started: Jul 1, 2026 Primary completion: Aug 31, 2026 Completion: Aug 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acute Myeloid Leukemia and Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and is currently actively recruiting participants. National Cancer Institute (NCI) leads this study, which shows 16 recorded versions since 2026 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2022 – ~Oct 2022 · 30 days · monthly snapshot~Oct 2022 – ~Dec 2022 · 2 months · monthly snapshot~Dec 2022 – ~Nov 2023 · 11 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~May 2025 · 2 months · monthly snapshot~May 2025 – ~Jun 2025 · 31 days · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – present · 5 months · monthly snapshot

Change History

16 versions recorded
  1. Mar 2026 — Present [monthly]

    Not Yet Recruiting PHASE2

  2. Feb 2026 — Mar 2026 [monthly]

    Not Yet Recruiting PHASE2

  3. Jan 2026 — Feb 2026 [monthly]

    Not Yet Recruiting PHASE2

  4. Sep 2025 — Jan 2026 [monthly]

    Not Yet Recruiting PHASE2

  5. Jun 2025 — Sep 2025 [monthly]

    Not Yet Recruiting PHASE2

Show 11 earlier versions
  1. May 2025 — Jun 2025 [monthly]

    Not Yet Recruiting PHASE2

  2. Mar 2025 — May 2025 [monthly]

    Not Yet Recruiting PHASE2

  3. Sep 2024 — Mar 2025 [monthly]

    Not Yet Recruiting PHASE2

  4. Aug 2024 — Sep 2024 [monthly]

    Not Yet Recruiting PHASE2

  5. Jul 2024 — Aug 2024 [monthly]

    Not Yet Recruiting PHASE2

  6. Jan 2024 — Jul 2024 [monthly]

    Not Yet Recruiting PHASE2

  7. Dec 2023 — Jan 2024 [monthly]

    Not Yet Recruiting PHASE2

  8. Nov 2023 — Dec 2023 [monthly]

    Not Yet Recruiting PHASE2

  9. Dec 2022 — Nov 2023 [monthly]

    Not Yet Recruiting PHASE2

  10. Oct 2022 — Dec 2022 [monthly]

    Not Yet Recruiting PHASE2

  11. Sep 2022 — Oct 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.